273 related articles for article (PubMed ID: 30786928)
21. Enhancer of zeste homolog 2 promotes hepatocellular cancer progression and chemoresistance by enhancing protein kinase B activation through microRNA-381-mediated SET domain bifurcated 1.
Zhou J; Che J; Xu L; Yang W; Li Y; Zhou W; Zou S
Bioengineered; 2022 Mar; 13(3):5737-5755. PubMed ID: 35184652
[TBL] [Abstract][Full Text] [Related]
22. LncRNA DBH-AS1 facilitates the tumorigenesis of hepatocellular carcinoma by targeting miR-138 via FAK/Src/ERK pathway.
Bao J; Chen X; Hou Y; Kang G; Li Q; Xu Y
Biomed Pharmacother; 2018 Nov; 107():824-833. PubMed ID: 30142544
[TBL] [Abstract][Full Text] [Related]
23. lnc-β-Catm elicits EZH2-dependent β-catenin stabilization and sustains liver CSC self-renewal.
Zhu P; Wang Y; Huang G; Ye B; Liu B; Wu J; Du Y; He L; Fan Z
Nat Struct Mol Biol; 2016 Jul; 23(7):631-9. PubMed ID: 27239797
[TBL] [Abstract][Full Text] [Related]
24. CircSETD3 (Hsa_circ_0000567) acts as a sponge for microRNA-421 inhibiting hepatocellular carcinoma growth.
Xu L; Feng X; Hao X; Wang P; Zhang Y; Zheng X; Li L; Ren S; Zhang M; Xu M
J Exp Clin Cancer Res; 2019 Feb; 38(1):98. PubMed ID: 30795787
[TBL] [Abstract][Full Text] [Related]
25. MiR-137 suppresses migration and invasion by targeting EZH2-STAT3 signaling in human hepatocellular carcinoma.
Huang B; Huang M; Li Q
Pathol Res Pract; 2018 Dec; 214(12):1980-1986. PubMed ID: 30274685
[TBL] [Abstract][Full Text] [Related]
26. Long Noncoding RNA
Chen X; Xie R; Gu P; Huang M; Han J; Dong W; Xie W; Wang B; He W; Zhong G; Chen Z; Huang J; Lin T
Clin Cancer Res; 2019 Feb; 25(4):1389-1403. PubMed ID: 30397178
[TBL] [Abstract][Full Text] [Related]
27. EZH2-mediated loss of miR-622 determines CXCR4 activation in hepatocellular carcinoma.
Liu H; Liu Y; Liu W; Zhang W; Xu J
Nat Commun; 2015 Sep; 6():8494. PubMed ID: 26404566
[TBL] [Abstract][Full Text] [Related]
28. MicroRNA-26a is a key regulon that inhibits progression and metastasis of c-Myc/EZH2 double high advanced hepatocellular carcinoma.
Zhang X; Zhang X; Wang T; Wang L; Tan Z; Wei W; Yan B; Zhao J; Wu K; Yang A; Zhang R; Jia L
Cancer Lett; 2018 Jul; 426():98-108. PubMed ID: 29653269
[TBL] [Abstract][Full Text] [Related]
29. Loss of tumor suppressor IGFBP4 drives epigenetic reprogramming in hepatic carcinogenesis.
Lee YY; Mok MT; Kang W; Yang W; Tang W; Wu F; Xu L; Yan M; Yu Z; Lee SD; Tong JHM; Cheung YS; Lai PBS; Yu DY; Wang Q; Wong GLH; Chan AM; Yip KY; To KF; Cheng ASL
Nucleic Acids Res; 2018 Sep; 46(17):8832-8847. PubMed ID: 29992318
[TBL] [Abstract][Full Text] [Related]
30. Long noncoding RNA PVT1 promotes hepatocellular carcinoma progression through regulating miR-214.
Gou X; Zhao X; Wang Z
Cancer Biomark; 2017 Dec; 20(4):511-519. PubMed ID: 28800314
[TBL] [Abstract][Full Text] [Related]
31. P53 suppresses the progression of hepatocellular carcinoma via miR-15a by decreasing OGT expression and EZH2 stabilization.
You Z; Peng D; Cao Y; Zhu Y; Yin J; Zhang G; Peng X
J Cell Mol Med; 2021 Oct; 25(19):9168-9182. PubMed ID: 34510715
[TBL] [Abstract][Full Text] [Related]
32. MiR-6875-3p promotes the proliferation, invasion and metastasis of hepatocellular carcinoma via BTG2/FAK/Akt pathway.
Xie Y; Du J; Liu Z; Zhang D; Yao X; Yang Y
J Exp Clin Cancer Res; 2019 Jan; 38(1):7. PubMed ID: 30621734
[TBL] [Abstract][Full Text] [Related]
33. lncRNA SNHG8 Promotes the Tumorigenesis and Metastasis by Sponging miR-149-5p and Predicts Tumor Recurrence in Hepatocellular Carcinoma.
Dong J; Teng F; Guo W; Yang J; Ding G; Fu Z
Cell Physiol Biochem; 2018; 51(5):2262-2274. PubMed ID: 30537734
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of Enhancer of zeste homolog 2 (EZH2) induces natural killer cell-mediated eradication of hepatocellular carcinoma cells.
Bugide S; Green MR; Wajapeyee N
Proc Natl Acad Sci U S A; 2018 Apr; 115(15):E3509-E3518. PubMed ID: 29581297
[TBL] [Abstract][Full Text] [Related]
35. CLDN14 is epigenetically silenced by EZH2-mediated H3K27ME3 and is a novel prognostic biomarker in hepatocellular carcinoma.
Li CP; Cai MY; Jiang LJ; Mai SJ; Chen JW; Wang FW; Liao YJ; Chen WH; Jin XH; Pei XQ; Guan XY; Zeng MS; Xie D
Carcinogenesis; 2016 Jun; 37(6):557-566. PubMed ID: 27207647
[TBL] [Abstract][Full Text] [Related]
36. PRMT5 functionally associates with EZH2 to promote colorectal cancer progression through epigenetically repressing CDKN2B expression.
Yang L; Ma DW; Cao YP; Li DZ; Zhou X; Feng JF; Bao J
Theranostics; 2021; 11(8):3742-3759. PubMed ID: 33664859
[No Abstract] [Full Text] [Related]
37. Enhancer of zeste 2 polycomb repressive complex 2 subunit promotes sorafenib resistance of hepatocellular carcinoma though insulin-like growth factor 1 receptor.
Hu J; Zhang J; Sun F; Qi M; Su P; Liu H; Gao L; Jiao M; Wu Z; Xiang L; Han B
Anticancer Drugs; 2019 Aug; 30(7):e0746. PubMed ID: 31305292
[TBL] [Abstract][Full Text] [Related]
38. miR-589-5p inhibits MAP3K8 and suppresses CD90
Zhang X; Jiang P; Shuai L; Chen K; Li Z; Zhang Y; Jiang Y; Li X
J Exp Clin Cancer Res; 2016 Nov; 35(1):176. PubMed ID: 27835990
[TBL] [Abstract][Full Text] [Related]
39. Epigenetic silencing of miR-144/451a cluster contributes to HCC progression via paracrine HGF/MIF-mediated TAM remodeling.
Zhao J; Li H; Zhao S; Wang E; Zhu J; Feng D; Zhu Y; Dou W; Fan Q; Hu J; Jia L; Liu L
Mol Cancer; 2021 Mar; 20(1):46. PubMed ID: 33658044
[TBL] [Abstract][Full Text] [Related]
40. Upregulation of miR-138 Increases Sensitivity to Cisplatin in Hepatocellular Carcinoma by Regulating EZH2.
Zeng T; Luo L; Huang Y; Ye X; Lin J
Biomed Res Int; 2021; 2021():6665918. PubMed ID: 33748276
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
